Journal for Re Attach Therapy and Developmental Diversities
eISSN: 2589-7799
2023 December; 6 (10s) (2): 1723 -1737

Revolutionizing Patient Outcomes with AI-Powered Generative Models: A New Paradigm in Specialty Pharmacy and Automated Distribution Systems

Karthik Chava[1*]

[1*]Senior Software Engineer, kkarthikchava@gmail.com, ORCID ID: 0009-0007-6001-4526

Abstract

Artificial intelligence (AI) large language models (LLMs) have been advanced with rapid advancements in science and machine learning techniques, increasingly leading to a wide range of high-level intelligent applications. Due to improved "understanding" of the context of writing prompts, AI LLMs for natural languages have been able to generate diverse and sophisticated organic text with remarkable fluency. LLMs are able to provide exceptional dialogue, vaccine material design, and academic text generation. The implementation of AI LLMs for pharmaceutical applications, however, such as prompt-driven language generation tasks in the pharmacy domain, have scarcely been attended to.

Recently, pharmaceutical patient specialists co-developed a new system, DrugSymphony, which was a language model based system of AI LLMs to enhance prompt-driven writing in the area of pharmacy. Two key complementary strategies around the specialized knowledge graphs and patient healthcare narratives can boost DrugSymphony, leading to inputs that mimic human knowledge comprehension. Through several evaluations utilizing patient sets in the real world, DrugSymphony is found to enhance well-defined tasks of writing, specifically medication program generation. It is hoped that this study will contribute to further research into machine-generated writing in the pharmacy field. At the time, however, the research sheds light on the effectiveness of LLMs in addressing real-world, professional-language, prompt-driven writing tasks, so pharmacy and pharmacotherapy specialists can maximally benefit from their potential functionality.

Recently, the implementation of advanced AI techniques for creating text has significantly improved the scope of potential applications in a broad range of sectors. The LLMs automatically generate organic text in response to a prompt of incoming text, with unprecedented fluidity and naturalness. The use of GPT has a great deal of flexibility; no specific instructions are often needed other than natural language text prompts. On this account, the beneficiaries include not only industry-insider professionals but also non-experts who may easily engage in building system prototypes for a wide range of applications. This includes technical reports, medical and science-related publications, company memoranda, marketing products, and so forth. GPT applications, on the other hand, come with the number of limitations: proprietary program formulation and large model costs.

Keywords: Specialty pharmacy, distribution systems, automated distribution, patient outcomes,AI-Driven Patient Outcomes,Generative Models in Healthcare,Specialty Pharmacy Innovation,Automated Medication Distribution,AI for Personalized Medicine,Pharmacy Automation Systems,Healthcare Optimization with AI,AI in Pharmaceutical Supply Chain,Patient-Centric Drug Distribution,Advanced Pharmacy Technologies.

1. Introduction

The use of AI in pharmacy is a topic that has the potential to revolutionize both patient outcomes and the ways in which pharmacist consultations are carried out. With the advent of large language models (LLMs), AI has taken significant strides forward in assisting with the generation of free-text describing optimal medication plans for patients, based on their medical information. The potential of AI-augmented generation models to enable the rapid, efficient generation of detailed plans - tailored to the individual patient's needs - allows for the opening of new avenues for personalized patient care. The research team is confident that the novel use of such models will have significant implications for pharmacy in the areas of automation of the supply chain, the growth of customized orders, and the generation of detailed advice from pharmacists.

The AI system, Hermies, has a number of prospective applications pertaining to point-of-service development. At its core, Hermies allows for the automatic creation of a patient-specific medication plan overview. Typically this could be passed to a patient after a consultation with a healthcare professional. In the context of a pharmacy, a patient can take the plan to the pharmacist to help lay the groundwork for their discussion. This would likely lead to a more fruitful consultation. Furthermore, in this scenario, Hermies could be pre-loaded with the patient history as supplied by the pharmacy, allowing for the immediate creation of the plan according to this data. That is, the pharmacist could come to the consultation with the plan already written, possibly paving the way for significant structural change in the way such consultations are carried out. The patient can also make the generated medication plan overview available to other pharmacy staff, who could take up the ongoing responsibility of creating/supplying medications in line with the generated plan.



Fig 1: Revolutionizing personalized medicine with generative AI

1.1. Background and Significance

In recent years, the use of artificial intelligence (AI) has seen a rapid increase across a plethora of fields including healthcare. AI and machine learning specifically have been widely embraced in silico studies for providing very effective and accurate predictions, assisting in decision-making, and drawing informative insights that would not be possible otherwise. In pharmacology and pharmaceutical research, AI has already been significantly successful, profoundly impacting drug discovery, development, and research. The AI pharmacist embodies opportunities and challenges beyond the model's capabilities across pharmacy operations and patient care. The deployment of a large-scale AI model in pharmacy practice demonstrates the importance of intertwining domain-specific expertise throughout development and emphasizes the importance of bespoke metrics for evaluating systems of this kind. The impact of the AI pharmacist can be deemed from a more comprehensive perspective where the model's support for a pharmacist service is accompanied by human inquiry answering and the generation of medication plans is a collaborative process over time. Delivery to pharmacies and care homes are facilitated via a bot system, where sets of generated medication plans can be easily formulated or edited and can answer questions about suggested medications or services, leading to the improved health and well-being of patients, as measured by their quality-adjusted life years. Co-distribution of vaccines and antibiotics, for instance, would not be recommended due to antibiotic interference with vaccine effectiveness. Adherence metrics are compared across different intervention groups: a group receiving prompts to take medication at the time scheduled by the pharmacy's Medication Plan, a group receiving the Medication Reminder Service, and a group receiving generating paths generated by the model.

Equ 1: AI-Driven Resource Allocation (ARA)

$$\mathbf{A}_i(t) = \arg\min_{\mathbf{A}_i} \left(\sum_{i=1}^{N} \left(\gamma_i \cdot [C_i(t) - E_i(t)]^2 \right) \right)$$

- $C_i(t)$ = Cost of allocation for patient i at time t
- $E_i(t)$ = Expected resource demand for patient i
- γ_i = Weight factor for patient i
- N = Total number of patients or units in the system

1.2. Research Objectives

A thorough literature review the research team conducted and analysis of the generated text reveal the tremendous potential of AI-powered language models in the field of medicine, but a fundamental knowledge gap persists in the real-world application of large language models in pharmaceutical operations and patient care settings. To fully explore this new field, the team has an agenda to integrate the capabilities of language models and domain expertise in a novel application. The ultimate goal is to generate multimodal outputs from AI models relevant to the pharmacy setting, consisting of textual and structured data, and to develop a methodology which can systematically ensure the products meet a predefined high standard. Real-world pharmacy operation improvements are achieved by developing a thorough

understanding of the specific pharmaceutical setting, so the constraints and requirements can be incorporated directly or indirectly during model training.
With the recent advancements in AI generative models, the applications of such technology in diverse fields have shaped a new epoch in the development of many industries. To orient these technologies in a validated process pertinent to clinical trials, protocol development is essential. A national public procurements conducted by institutions needs to survey available solutions for development of these protocols. Significant improvement in efficiency, accuracy, and the customization of the protocol to clinical trial requirements is observed.

2. AI-Powered Generative Models in Specialty Pharmacy

The unprecedented development of artificial intelligence (AI) technologies is revolutionizing the healthcare industry, and its transformative path is continuously entering uncharted territories. Specialty pharmacy, which focuses on delivering specialized drugs in the treatment of complex, chronic conditions, stands to markedly benefit from these new technologies. AI-powered generative models, which have excelled in drug discovery and molecular optimization, are particularly poised to rewrite the state of the art in specialty pharmacy. Distributors and integrators of medication play a key role in the pharmacy-sphere, ensuring a comprehensive medication delivery to patients. An automated system powered by generative models is proposed as a novel paradigm for specialty pharmacy operations that encompasses an end-to-end solution for medication plan generation, automatic drug packing, and optimized delivery route planning. It is envisioned that enhanced with generative models and large language models (LLMs), automated distribution networks could markedly improve patient outcomes and pharmaceutical operations.
On the pharmaceutical side, a model is developed to generate optimized medication plans based on patients' personal data and health conditions. These plans are subsequently transferred to a drug packing robot, which prepares the packages for delivery. In parallel, a distribution system reminiscent of an autonomous robot fleet is developed to automate the delivery tasks. The specification of all models and the pipeline demands a particular focus on the realization of interpretable and data-efficient architectures. The complexity of the entire layout is moderated, as feasibility in real-world settings is highly desired. Customized lightweight design of generative models is proposed, specifically tailored for the demands in the field of pharmacy. Major innovations and potentials of such models in pharmacy applications are explored, promising to advance the integration of AI with pharmacy.

2.1. Definition and Functionality

Specialty pharmacy deals with complex medication therapy regimes, often via specialty drugs that require special handling and administration. As an individualized and intensive clinical service, care is provided to the patients seen both in routines and in more complicated long-term needs on a continuing basis, something that is often not readily available, or affordable. To date, solving such a problem involves automatically filling repeat prescriptions to reduce staff stress, expediting pharmacy operations, and reaching immediate satisfaction of patient needs.
Generative Pre-trained Transformers (GPT) has created a notable progression in large-scale language models. This technology is used to investigate how it can be applied in specialty pharmacies to improve medication plans. The incorporation of large language models significantly enhances the precision, personalization, and efficiency in creating medication plans for patients, potentially leading to improved patient results. This methodology integrates patient health data, generating a medication plan that outlines details on when, how, and what medications the patient should take. Specialty pharmacy professionals need to provide patients with personalized, compliant, and optimized medication schedules, a highly time-consuming and demanding task. Large language models (LLMs) that provide a vast amount of labeled patient health data can robustly improve efficiency in creating a well-performing and personalized medication plan model. Meanwhile, the potential for better patient results and the facilitation of running pharmacy operations are highlighted.
However, by integrating GPT in specialty pharmacy, caution is needed to apply the expertise of specialists output to instruction encoding. It is crucial to have expert knowledge consolidation in the form of multi-input positional encoding. As such, an in-depth focus is given to medication plan creation as a specialty pharmacy task, including the design and explanation of repeat prescription schedules as a specialty pharmacy service, and the development of careful metrics to evaluate the performance of generated medication plans. In the transformation of medical data into natural language, a new language processing task, there is still space for exploration in T5 fine-tuning strategies in handling pharmacy data with significance.

2.2. Applications in Specialty Pharmacy

One of the undeniable tasks performed by humans, or AI-powered Generative models working in conjunction with humans, is the modeling and deployment of medication regimens. For the bulk of this article, we will focus on the potential implications of leveraging language generative models, using these models to design a new automated system for pharmacy, and discussing the vision and expected challenges of embedding such advanced models into the existing pharmaceutical world. As what to generate both depends on individual cases and the accompanying language models playing BERT-inspired tricks, the generation process takes the form of commercial drugs, ingredients/quantities, and free-text news/instructions. This means that the patient's situation or the existing drugs prescribed are the inputs to this system.

This exploration into a novel area will be theoretical in explaining the operation of generative models or methods applied to pharmacy, be large-scale, parametric, pretrained generative models with particular focus on the GPT family, and be applicative in presenting a detailed design and set of requirements for an effective model to generate medication plans and support various master/slave task models. The first automated specialty chemistry platform powered by AI conversational will be discussed, an example system of injecting pharmacy grade API into leading B2B, and demand e-prescription and pharmacy system interface. A great potential exploration of fundamentally reshaping expert intense healthcare areas can result from insights into emerging integrations of AI with pharmacy.



Fig 2: Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery

2.3. Benefits and Challenges

Specialty pharmacies distribute medications that require special handling, storage, or monitoring. These can be used for complex treatments such as cancer, rheumatoid arthritis, or multiple sclerosis. Automation may simplify the return process and improve environmental stewardship. While specialty pharmacy patients often experience high levels of trial and error, there are significant improvements that can be made in terms of outcomes for automated distribution systems. Specialty pharmacy distribution frequently involves high-cost medications. The need for a prescription, combined with requirements for special storage or handling, necessitates the involvement of a pharmacist for much of the distribution process. Improved handling of the return process holds potential for increased efficiency across the board. In a situation where a patient fails to tolerate a medication or the medication is not effective, the medication is typically returned to the specialty pharmacy, to be disposed of or returned to stock inventory. Automation could simplify these processes. Additionally, improper disposal can create environmental hazards. This problem aligns with a pharmacy benefit manager (PBM) with a network of independent specialty pharmacies, which are seeking approaches to improve patient outcomes, for example, in terms of reducing the amount of trial and error experienced by patients. Each patient is using a sequence of treatments through a specialty pharmacy. In this problem, a treatment is defined as a prescription. When a patient is unsuccessful with a treatment, they are moved to the next treatment in the sequence. Parameterized algorithms are used to learn sequences of treatments for patients, which aim to maximize the falls in trials before success experienced by patients. However, the high malleability of these methods implies that even a model with as many as 175 B parameters could be memorized in one training epoch. Examples include parameter deduplication and sparse expert models; in the present case, room for such complexity or malleability is limited, but the interest is raised for future research. An unrivaled ensemble of 1892 language models is trained and evaluated. When this model is exposed to experimental voting protocols with human subjects, it outperforms a majority vote of 25 experts. There is room for future research on how regulators could elect such large models to increase consensus or to extend the experimental protocol. Each protocol contains the information required to conduct the study and interpret the findings. However, protocol authoring is a time-consuming and challenging task, involving input from numerous stakeholders.

Journal for Re Attach Therapy and Developmental Diversities
eISSN: 2589-7799
2023 December; 6 (10s) (2): 1723 -1737

3. Automated Distribution Systems in Healthcare

Recent advancements in artificial intelligence are revolutionizing patient outcomes by combining big data about patients with AI-powered generative models to generate tailor-made improvement strategies. By unifying the two, a new bi-directional approach emerges, where the generative model can not only generate prescription plans but also fairly predict their outcomes for the patient on which they are generated. This novel concept illuminates a new paradigm in which healthcare and distribution systems are integrated, thus enabling the distribution of medication plan sequences to patients. Here, this new concept is theorized broadly as an "automated distribution system as a service," which could be implemented in various sectors such as drones and employs robots in manufacturing tech. The pharmaceutical sector has yet to experience a leveled-up intelligent transformation; such a revolution is expected to be of broad-spectrum nature and will change the specialty pharmacy sector perhaps the most fundamentally. Specialty pharmacy is uniquely positioned with its chain of distribution centers to integrate with the emerging AI systems en masse since mass-scale integration is a prerequisite. To deeply understand and formulate the implications of AI-powered generative models, a multi-faceted examination of automated distribution systems in healthcare is conducted. This holistic probing has mainly inspired the establishment of a knowledge base at the intersection of these two paradigm shifts in the field of study.

3.1. Overview and Importance

Since the time pharmacies first spread the word on their healing services, the practice of pharmacy has remained comparatively unchanged for thousands of years. In today's society, pharmacy remains tied to tradition. Undercover, synthetic compounds are obtained and utilized to create a cure for humanity's many ailments, following criteria closely adhering to those set forth in the Hippocratic Corpus. However, one modern condition has dramatically evolved: the understanding of biology and the generative creation of compounds have surpassed the limits of tradition and manual implementation.

Today's pharmacology is a data-driven, automated, and digital field simultaneously advancing at a rapid pace. In the past several years, pharmacies have seen a massive influx in drug costs, often due to corporate greed. The traditional retail pharmacy setting has been a notable target of this trend; the complex insurance schemes and reimbursement rates have made it difficult for small pharmacies to survive. What's more, the rigid manual schedule of traditional pharmacies allows a limited array of service offerings and tasks. This renders it nearly impossible for pharmacies to revolutionize patient outcomes using data-driven approaches. Not to mention, care for the most complex of medications and patients, those with chronic conditions necessitating specialty medicines, can't be provided by general retail pharmacies. With these challenges in mind, pharmacies, pharmaceutical companies, and healthcare providers can still prepare for radical advancements in pharmacy and medication distribution.

3.2. Types of Distribution Systems

Specialty Patient Therapy requires a sophisticated distribution system, possible only because tech companies are now capable of releasing models that apply many copying predictions to further applications and correlate the prediction with the probability of fulfilling it. Generative models power essentially algorithmic Speciality Pharmacy and Distribution System when encoding models instead of formula genotyped data that typically apply copied numbers within proprietary Order Management Systems for commercial gain and connectivity. Distribution systems are a natural extension of such models, making implementations available as add-ons to establish parts of the technology. These are of applications in various distribution systems, each targeting exponentially growing commercial speciality therapies from biotechnology companies to treat prevalent chromosomal defects in the U.S.A.. Regarding the pharmaceutical industry, restricted distribution is essential in maintaining brand loyalty and high prices. Applied custom COPYCAT models on Order Verification Request data from four captive specialty pharmacies in top hospital systems, revealing complexity in aggressiveness, responsiveness, and compliance across pharmacies even in regions defined by the same OEM as a shocking compliance for routine production stop that are hardly penalized below needed to incentivize compliance. Similarly to other existing research on incentivizing compliance to distribution models, unprecedented detail and insights are shown not only due to fine-grained modeling and custom, but also because extensive consulting operations provide insights on proprietary distribution mechanisms. Most of the large medications administered to patients at hospital are delivered from the pharmacy. discussed that activities related to purchase, constituent of the formula, storage and distribution system that go way beyond the classic pharmaceutical consultation, translate officially into the hospital's activity. Because more need, more opportunity, more product, and cost. Developing the hospital business in this line, requires strategic planning and expansion of facilities or improvement of processes. This was an opportunity to experiment and find your place in the local market in a strategic niche. Unfortunately, it is also necessary to implement various types of automation. With reference to the distribution systems, each should be considered individually introduced into the hospital, selecting systems to support the hospital model and optimization options etc., are discussed.

Fig 3: Large language models (LLMs) in medicine

3.3. Advantages and Limitations

Artificial Intelligence and Machine Learning in Pharmacological Research: Bridging the Gap Between Data and Drug Discovery

Today, the search for connections in a data-based approach in the field of pharmacology plays a very important role in optimizing the discovery of drugs and their introduction into therapy. The generation and analysis of pharmacological data is a complex and time-consuming process. Thanks to the use of AI models, including machine learning (ML) and natural language processing (NLP), it is possible to accelerate the process of acquiring knowledge about the amount of generated data. The analysis and exploration of the data generated within large databases became possible thanks to algorithms based on artificial intelligence. They enable accurate and comprehensive research such as discovering patterns, correlations, or new insights. Development of analytical methods in the field of artificial intelligence has led to the widespread use of predictive models. Using them, it is possible to analyze big data, specifically predicting and making decisions based on the available data. AI systems have repeatedly proven their importance as tools for improving progress, providing a number of practical advances. At present, it is difficult to imagine successful pharmacological research and its practical applications without the use of AI-models. Currently, one of the most dynamically developing industries is the application of artificial intelligence. In the pharmacological industry, such systems help in a more thoughtful process of introducing new drugs and a better optimization of therapy very quickly. Innovative medicines are pharmaceutical innovations mostly in demand in high-quality healthcare systems and usually focus on the treatment of the most serious illnesses. Modeling complicated variables and numerous likely affecting elements and strong efficacy dependence on them is a complex issue.

Equ 2: Optimization of Resource Allocation in Automated Distribution

$$\text{Efficiency} = \frac{\sum_{k=1}^{N} \text{Demand}_k}{\sum_{j=1}^{M} \text{Resources}_j}$$

Where:

- Demand_k is the quantity of medication required by patient k,
- Resources_j is the amount of resource used (e.g., human resources, space) for fulfilling a distribution task j,
- N is the number of patients,
- M is the number of available resources.

4. Integration of AI and Automated Distribution Systems

Artificial Intelligence (AI) and Generative models leveraging reinforcement learning and rule-generated probabilities have already been vast in the discovery of potential drug candidates. Specialty pharmacy, a facet of pharmacy benefit management (PBM), faces growing interest with the rise of highly specialized biopharmaceuticals, as they help to cater tailored solutions to complex illness. As the COVID-19 pandemic continues to stretch the capabilities of the healthcare system, interest in AI for drug discovery applications has surged again, fueled by an urgent desire to accelerate drug development. Although vaccines are a key element in controlling COVID-19, there are currently no drugs approved by the US Food and Drug Administration (FDA) to treat the viral infection. Many challenges are present in the development of COVID-19 antivirals, including a lack of tractable targets, difficulties in identifying effective compounds from the broad spectrum of potential drug candidates, and a need to consider the rapidly evolving situation.

At the same time, innovations in AI models are making it ever easier to process a large amount of medical data and model complex relationships, enabling applications in every aspect of drug development from target identification to literature review. One promising area for improvement using state-of-the-art AI is the development of generative models capable of synthesizing or generating data, such as text, using the amplification of a large pre-trained language model, improved transfer learning approaches, and better optimization techniques based on rule-generated probabilities. Through the integration of blockchain, current medical data can be stored securely and its integrity can be ensured. The eighteenth year of this century has also seen a combination of AI and blockchain in promises to revolutionize research areas, including open-access publishing, preclinical animal experiments, and clinical trials. AI and generative models leveraging reinforcement learning and rule-generated probabilities are anticipated to galvanize a new wave of revolution in the discovery of potential drug candidates.

4.1. Synergies and Benefits

Recent advancements in artificial intelligence (AI) and machine learning have enabled the development of generative models capable of automating the production of large-scale textual outputs. These models have already been adapted to revolutionize numerous professional domains, and their successful application has inspired enthusiasm to adapt them to the discipline of pharmacy. Special attention has been given to medication plan generation within the context of specialty pharmacies and automated distribution systems.

Significant synergies and benefits will result from the incorporation of generative models into these operational paradigms. In particular, tailored AI-powered systems guiding pharmacy staff in the selection and preparation of medication parcels for patient care will be discussed. The complexity of orally conveying numerous nuanced medication directives will facilitate increasingly complex hour-by-hour dosing regimens, as well as compound medications demanding the mixtures of various active ingredients. Broadly, this article aims to lay the foundations for the generation of next-gen medication generation systems in the pharmacy domain, supporting future interdisciplinary AI and pharmaceutical research endeavors.

Unleashing the true potential of large language models will require carefully considered architecture development and adaptation. A scala-flow is outlined in conjunction with suggestions for model enhancements, ensuring pharmacy-relevant outputs. Developed with great fanfare but withdrawn less than a week later due to concerns over uncivil back-and-forth exchanges, Microsoft’s Tay will always remain the benchmark for AI-born absurdity. Phonetically identical but homophobically different from an apparent bodily organ, the young model’s naive conversations quickly took a downturn that many had foreseen but the company failed to preempt. Indeed, the first-ever allotransplantation of Twitter immaturity into NLP systems; a rave RT now 4 scale.

4.2. Technological Challenges and Solutions

To address patient-specific adherence risk factors and inform precise medication therapy management (MTM) interventions, sophisticated health informatics tools are needed. Highly accessible electronic health records (EHR) APIs can be leveraged to compute indicators of adherence complexity from time-varying data sources, predict unplanned healthcare use due to non-adherence, and generate tailored suggestions to discuss with patients.

The burden for payers and providers desiring to implement specialized, expensive health informatics tools is reduced by demonstrating the feasibility of realizing the tools using simple EHR features. Pharmacy-based adherence complexities are proposed using distance-entered pharmaceutical care plans and pharmacy claim transaction records. With national patient data, a predictive model is trained for and validated in the top quartile of US health systems. APIs-related indicators are built to monitor pharmacy-based complexities. When adherence events are planned, the tool advises refactors to mean adherence amortization from the patient, reducing subsequent healthcare use.

A LINCS-based model designed to evaluate model performance on in-sample data, following patterns of false positives and negatives, is applied to the generated data. This methodology and the underlying model could be useful for the translational application of other health informatics tasks. The model must be evaluated on actual out-of-sample data, though promising evidence is provided that LinCGQMTP reduces robustly measured garbage outpatient ED visits, suggesting the approach has the potential to enable comprehensive MTM for patients.



Fig 4: Grand Challenges for Artificial Intelligence in Molecular Medicine

5. Case Studies and Real-World Applications

This collaboration between the Roche ComVE specialty pharmacy and the High Tech Systems Center embarks on a mission to revolutionize and streamline patient management protocols through the development and integration of generative AI technologies. As a result, these state-of-the-art multi-level and multi-industry collaborations have adopted a synergetic approach that combines the industrial knowledge and expertise of Roche ComVE with cutting-edge AI tools of the High-Tech Systems Center. It is postulated that such a unique synergy can further improve and expedite the personalized and precise nature of patient management protocols. Moreover, the paradigm shift toward a patient-centric view, intelligent clinical decisions, and the automatic adjustment of treatment cycles will positively alter current patient management strategies. Hence, the main objective of this joint collaboration is to develop and implement real-time patient symptom-outcome prognostic and decision-making models for patients with cardiovascular disorders. In more detail, these models are to smartly predict the future patient state by quantifying blood markers, heart sound recordings, and other patient signals. Furthermore, the prognosis result (patient outcome and confidence level) is made available to expert users, which eventually empowers them to optimally recommend the corresponding intervention strategies. Meanwhile, a novel type of automated medical device will be developed and integrated at the smart hospital center: healthcare workers only need to input each patient's ID to receive patient-specific recommendations. Moreover, a ConVE AI-enabled system will automatically adjust the treatment and follow-up intervals, and bed types of all relevant patients, thereby ensuring that such adjustments are truly optimized and sensible. Furthermore, state-of-the-art decision support systems and clinical trial protocol authoring AI technologies will be deployed and refined to further improve protocols and streamline the above-mentioned treatment adjustment mechanisms. In conclusion, the execution of the above plans is expected to significantly raise the level and standard of care given to all relevant patients and allow for a faster but still targeted response to incoming patients.

Fig 5: Use Cases of Generative AI in Healthcare

5.1. Success Stories in Specialty Pharmacy Through modularity, the mechanism might be used in automated systems to fill selected medications, which when combined could offer the potential for a simple and precise implementation of Thompson sampling, or other policy optimization frameworks for pharmaceutical applications. The ability to either replenish a newly depleted compartment, or actively rotate various medications through a unit dose could foster diverse global optimization strategies. Such a mechanism might benefit from a token mechanism, with machine learning-based decisions, as well as the potential integration of robotics for a pre-manufactured set of unit doses. The use of a screw mechanism might also provoke more random exploration of the full storage space, and thus the mechanism would extend naturally to both inventory management and medication prefabrication.
Another AI-powered study investigated the competitive advantage of various virtual small molecules in development by assessing substituent similarity to prominent marketed drugs. For a total of 1287 marketed drugs, US patents were obtained for the 150 most similar new virtual drugs that are assisted by large Transformer-based generative language models. A significant return on investment was later found, providing support for the use of such generative models to aid drug repurposing. Robotic pill dispensing systems optimize costly research collaborations between academia and industry by evaluating the potential membrane permeation of over 500 drugs that are not expected to be marketed until 2026.

5.2. Innovative Use of AI in Distribution Systems
Distribution systems in specialty pharmacies are transitioning from predominantly utilizing health care provider pharmacies to employing commercial pharmacies, with automated systems further streamlining these new paradigms. In transitioning from provider to commercial pharmacies, the onus on quality drug design falls more on the hands of pharmaceutical firms. Although much research has been devoted to using deep learning approaches to generate diverse molecules, the relatively low success rate of generated candidates that receive approval for clinical trials often provides insufficient candidate pools for commercial pharmacy applications. To address this gap, this research employs a transformer based architecture followed by reinforcement learning to generate novel molecules in the context of oncology drug discovery. To the best of current knowledge, this is the first study to utilize novel templates and reinforcement learning to optimize design of drug candidates.
With the advance of machine learning and generative model approaches, researchers are able to utilize novel methods for unique drug discovery. Six novel templates representing known drug bioactivity make it possible to train agents to perform synthesis action sequences that should lead to the identification of bioactive molecules. These templates guide the reinforcement learning agent to connect molecular representations of library molecules to a desired output. This innovative approach is the first that is known that interfaces generative models with known templates and reinforcement learning to optimize the discovery of drug candidates. Following the methods described, future work should find evaluation on different machine learning approaches or their combinations to generate novel designs. Furthermore, improving the reward function to direct optimization towards more desirable properties could yield more realistic candidate designs. Additionally, this framework could be applied to a different library of chemical compounds to facilitate a more general utilization of this approach.

Equ 3: Automated Drug Distribution Optimization

$$C = \sum_{k=1}^{N} (C_k + T_k)$$

Where:

- C is the total cost of distribution,
- C_k represents the cost of distributing medication to patient k,
- T_k represents the time taken to deliver medication to patient k,
- N is the total number of patients.

6. Ethical and Regulatory Considerations

Research in AI and machine-learning models addressing challenges in pharmacological research is discussed, as well as the ethical considerations of incorporating these models. There is a growing trend of using black-box AI models in the industry to guide important decisions. These models are difficult to interpret and their lack of transparency can be prohibitively restrictive for enabling their use. This paper introduces three open-source machine-learning interpretability packages useful in revealing drug design and healthcare consumers' response factors in data-driven tasks, with a particular focus on the local interpretable model-agnostic explanations method. Encouraging trust in decisions enabled by complex predictive systems is essential for AI-powered decision-making in domains like drug discovery, in order to avoid potentially harmful consequences. The exploration of transparent and interpretable black-box models for automated text classification is described and made available as an open-source package for the R platform, labeled 'interpretable-text'. It is shown how, with only minor adjustments to the inputs, undesirable attributes of the classification system are exposed. As an alternative, rule-based systems for text classification are explored, not showing a similarly high level of model agnosticism but instead providing deeper insight into the classification process. The method is applied to illustrate consumer-drug reaction causality, with proposed guidelines for the design of "consumer-friendly" drug information formulations. The paper also illustrates how the transparency of a predictive model might be exploited by malicious actors, and how pharmaceutical companies can protect their intellectual property in this context.



Fig : Generative AI Meets Healthcare

6.1. Privacy and Data Security

The rapid digitalization of health data and the increasing adoption of electronic health records (EHRs) have opened new opportunities to leverage data-driven insights and innovations to enhance the quality and outcomes of patient care. Despite the growing focus on patient privacy in healthcare, significant opportunities remain to improve digital systems and practices. In instances where a patient's health or personal information is processed or shared, it is important that this is managed in a transparent, secure and confidential manner. With the shift towards digital assessment and treatment technologies, particularly with the increased telehealth adoption and development of AI-powered applications, the amount of digital health data recorded, shared or interpreted will increase significantly. These sensitive data types have a corresponding increase in security risks since it expands the potential electronic access points open to criminals or unauthorized parties to exploit and profit from. With highly sensitive patient health data transferred and shared more frequently in digital form, the security and integrity of this data is paramount. The potential ramifications of a patient's health data exploited or manipulated are vast and potentially life-threatening.

Large-scale, multi-center, multi-modal data-driven research in the area of neurodegenerative imaging biomarker development raises the need for data systems that comply with European data protection laws. For the European Union, the General Data Protection Regulation (GDPR) aims to give control to individuals over their personal data and to simplify the regulatory environment for international business. It harmonizes data protection rules in the EU and is designed to protect people's privacy, in the face of increasing concerns about the scale of data breaches and inappropriate use of personal data in the commercial sector. The resources developed for data sharing should be compliant not only for user data containing personal information but also for the underlying database. Proper de-identification is therefore essential to ensure that subjects cannot be identified by any member of the data shared. This requires extensive effort before sharing and further processing of the requested data.

6.2. Compliance and Legal Frameworks

Pharmacological treatment inherently is complex, covering issues of drug combinations, comorbidities, and precision medicine. Furthermore, insurance providers impose guidelines on providers and prescriptions. As a result, pharmacological treatment is hard to interpret by AI. In such scenarios, concerns often arise about the decision's compliance with treatment guidelines and legal regulatory frameworks. Currently, the development of AI in the medical domain has proceeded into reinforcement learning, deep learning, and generative neural networks, passing through a crisis of foreign substance prediction models and developing into generative models. Generative models that the deepest learning is evolving are facing the expected flow of being most active in pharmacological research. Extremely, GAN can structure a generator who can create fake information that is convinced to be real. With VAE, an encoder and a decoder are educated, thereby automatically creating similar compounds from a small number of target compounds.

However, the explainability for the generative model has always been questioned, considering that it is intended to be one of the black boxes. In the wider sense, this fact limits trust in the decision. The solution is proposed combining rule-based systems and LIME. The rule-based system is in favor of drafting rules by analyzing the produced molecules. Also, LIME processes the local input into a computationally easy representation to replicate the decision made by the black box model.

7. Future Directions and Conclusion

With the rise of advanced Pharmacy Robots, New GPT-3 technology, and the medicine industry as a whole increasing 24% every year, it's very important to look to the future and forecast what's to come. The three industries where these technologies intersect, the "Sweet Spot", have already begun the discovery of how big of an impact they can have not only on speeding up the time it takes for patients to receive specialized medicine, but also making the entire process infinitely more easy. With great power comes great responsibility, and in diving into the world of Pharmacy Robots and GPT-3 and what they can achieve for Specialty Pharmacies, the long list of work that still needs to be done becomes apparent. The big picture is to gain a sense of how complex systems of Pharmacy Robots, Generative Language Models, and Distribution Systems can work together in Specialty Pharmacies, beef up drug knowledge, and predict what the impacts will be on patient outcomes.

Pharmacies can utilize incoming patient data to funnel the jobs of Pharmacy Robots. The patient drops off the prescription, the green flag goes up ordering the drug, the robot drops off the drug and the green flag goes down. Once the patient picks up the drug, another green flag goes up and the prescription is delivered to the patient. It doesn't make sense to order the drug until the patient has completed a conversation with a pharmacist. This makes the incoming patient data incredibly useful in informing the process of the Pharmacy Robots. The more incoming data involved in the process, the smarter the robot, the easier it is to implement in an environment.

Data is the Simplest Foundation to Start Building on. After understanding where the potential bottlenecks could be, it becomes clear that overall the safety and seamless process of interacting with patients is of the utmost importance. With this in mind, the GPT-3 model PharmacyGPT was created, imagining it being trained long term on the same incoming patient data the Pharmacy Robots use, alongside as much drug knowledge as possible. At the core of a robot's function is the need to match what is desired of it (and why) with the correct safety regulations. A constant influx of more accurate drug knowledge is necessary to best guide interactions. Further work involving creating more accurate drug knowledge can involve associating each piece of drug knowledge with a DRUG ID number, and informing both the training data and the GPT-3 model when dispensing happens around that drug, for what reason, and why.

7.1. Emerging Trends and Opportunities

The specialty pharmaceutical sector is expected to continue growing for the foreseeable future, spurred by more new drug therapies being introduced to treat various chronic illnesses, skyrocketing healthcare costs, and the sanctioned use of biosimilar drugs as comparable and more affordable alternatives to brand-name biologics. In 2023, the specialty pharmaceutical industry was estimated to have accounted for 46.4% of the total US sales of prescription drugs, up from 37.1% in 2013 and forecast to hit 51% of the $610-billion drug market in 2026.
The Pharmaceutical Care Management Associated (PCMA) has projected the share of specialty drugs within the pharmacy industry’s net cost to grow to 50% or more by 2026. Given the escalating number of clinical trials and research publications, the relationships between hundreds of drugs and disorders have become increasingly complex. The interdisciplinary insight into the chemical ingredients that compose individual drugs has been traditionally confined to pharmacology departments, considered impervious to the general public. Despite the availability of an array of compendia and electronic reference sources on pharmaceuticals, unique insight into mass-market trends about the effects and cost efficiency of various drugs, especially newer drugs, and assignments to specific patient demographics has remained somewhat arcane.

7.2. Key Takeaways and Recommendations

Specialty pharmacies, and more generally the automated distribution systems, have the potential wealth of data to leverage generative models for the accurate prediction of both patients and disease progression. However, such applications are limited both by the commercialization intent of current pharmaceutical companies and the lack of public datasets capturing the dual-faceted distribution at patient-level, e.g., both temporal patient treatment plans and outcomes, such as test results, derived disease states, and lab visits. Inspired by PharmacyGPT, our approach leverages a large language model (LLM) to generate individualized patient treatment plans based on expert knowledge through a precisely designed training task structure. It trains PharmacyGPT on a large corpus extracted from extract-transform-load (ETL)-parsed records of patients with chronic kidney disease treated at various outpatient local distribution pharmacy providers. Such treatment plans are presented to be comprehensive and chronological including both therapy names and dosages yielding valid predictions of drug adherence. Model development focused on the application of LLM in pharmacy such that a great potential is believed in this direction and it should be quite lucrative to start shaping it right now, ahead of the societal ramp-up of interest. Additionally, the broader community can benefit from some discoveries laid out during the research, regular and easy-to-replicate model training with emphasis on incorporating expert knowledge, smoothing medication embedding to inpainting, task structure, medications used to bootstrap the model, data preprocessing, the Table of Descriptors. A patient that had been exposed to a physician in charge of drug therapy had a drug therapy plan generated by LLM, PharmacyGPT. With the drug therapy arm of a randomized trial analysis, patient adherence was predicted for the generated drug therapy plan. The research opens up “black-box” abilities of LLM and PharmacyGPT to treat pharmacy-related tasks. Those will include recommendations on both how to approach translation of a task into LLM form and field studies on evaluating a solution that will help understanding weaknesses and limitations of generated treatment plans.

8. References

[1] Laxminarayana Korada. (2023). Role of 5G & Edge Computing in Industry 4.0 Story. International Journal of Communication Networks and Information Security (IJCNIS), 15(3), 366–377. Retrieved from https://www.ijcnis.org/index.php/ijcnis/article/view/7751
[2] Eswar Prasad G, Hemanth Kumar G, Venkata Nagesh B, Manikanth S, Kiran P, et al. (2023) Enhancing Performance of Financial Fraud Detection Through Machine Learning Model. J Contemp Edu Theo Artific Intel: JCETAI-101.
[3] Siddharth K, Gagan Kumar P, Chandrababu K, Janardhana Rao S, Sanjay Ramdas B, et al. (2023) A Comparative Analysis of Network Intrusion Detection Using Different Machine Learning Techniques. J Contemp Edu Theo Artific Intel: JCETAI-102.
[4] Vankayalapati, R. K., Sondinti, L. R., Kalisetty, S., & Valiki, S. (2023). Unifying Edge and Cloud Computing: A Framework for Distributed AI and Real-Time Processing. In Journal for ReAttach Therapy and Developmental Diversities. Green Publication. https://doi.org/10.53555/jrtdd.v6i9s(2).3348
[5] Reddy, R. (2023). Predictive Health Insights: Ai And Ml's Frontier In Disease Prevention And Patient Management. Available at SSRN 5038240.
[6] Nampalli, R. C. R. (2023). Moderlizing AI Applications In Ticketing And Reservation Systems: Revolutionizing Passenger Transport Services. In Journal for ReAttach Therapy and Developmental Diversities. Green Publication. https://doi.org/10.53555/jrtdd.v6i10s(2).3280
[7] Syed, S. (2023). Shaping The Future Of Large-Scale Vehicle Manufacturing: Planet 2050 Initiatives And The Role Of Predictive Analytics. Nanotechnology Perceptions, 19(3), 103-116.
[8] Korada, L. (2022). Using Digital Twins of a Smart City for Disaster Management. Journal of Computational Analysis and Applications, 30(1).

[9] Janardhana Rao Sunkara, Sanjay Ramdas Bauskar, Chandrakanth Rao Madhavaram, Eswar Prasad Galla, Hemanth Kumar Gollangi, et al. (2023) An Evaluation of Medical Image Analysis Using Image Segmentation and Deep Learning Techniques. Journal of Artificial Intelligence & Cloud Computing. SRC/JAICC-407.DOI: doi.org/10.47363/JAICC/2023(2)388

[10] Kalisetty, S., Pandugula, C., & Mallesham, G. (2023). Leveraging Artificial Intelligence to Enhance Supply Chain Resilience: A Study of Predictive Analytics and Risk Mitigation Strategies. Journal of Artificial Intelligence and Big Data, 3(1), 29–45. Retrieved from https://www.scipublications.com/journal/index.php/jaibd/article/view/1202

[11] Danda, R. R. Digital Transformation In Agriculture: The Role Of Precision Farming Technologies.

[12] Syed, S. Big Data Analytics In Heavy Vehicle Manufacturing: Advancing Planet 2050 Goals For A Sustainable Automotive Industry.

[13] Gagan Kumar Patra, Chandrababu Kuraku, Siddharth Konkimalla, Venkata Nagesh Boddapati, Manikanth Sarisa, et al. (2023) Sentiment Analysis of Customer Product Review Based on Machine Learning Techniques in E-Commerce. Journal of Artificial Intelligence & Cloud Computing. SRC/JAICC-408.DOI: doi.org/10.47363/JAICC/2023(2)38

[14] Sondinti, L. R. K., Kalisetty, S., Polineni, T. N. S., & abhireddy, N. (2023). Towards Quantum-Enhanced Cloud Platforms: Bridging Classical and Quantum Computing for Future Workloads. In Journal for ReAttach Therapy and Developmental Diversities. Green Publication. https://doi.org/10.53555/jrtdd.v6i10s(2).3347

[15] Ramanakar Reddy Danda, Z. Y. (2023). Impact of AI-Powered Health Insurance Discounts and Wellness Programs on Member Engagement and Retention. Letters in High Energy Physics.

[16] Syed, S. (2023). Zero Carbon Manufacturing in the Automotive Industry: Integrating Predictive Analytics to Achieve Sustainable Production. Journal of Artificial Intelligence and Big Data, 3, 17-28.

[17] Nagesh Boddapati, V. (2023). AI-Powered Insights: Leveraging Machine Learning And Big Data For Advanced Genomic Research In Healthcare. In Educational Administration: Theory and Practice (pp. 2849–2857). Green Publication. https://doi.org/10.53555/kuey.v29i4.7531

[18] Polineni, T. N. S., abhireddy, N., & Yasmeen, Z. (2023). AI-Powered Predictive Systems for Managing Epidemic Spread in High-Density Populations. In Journal for ReAttach Therapy and Developmental Diversities. Green Publication. https://doi.org/10.53555/jrtdd.v6i10s(2).3374

[19] Danda, R. R. (2023). AI-Driven Incentives in Insurance Plans: Transforming Member Health Behavior through Personalized Preventive Care. Letters in High Energy Physics.

[20] Nampalli, R. C. R. (2022). Neural Networks for Enhancing Rail Safety and Security: Real-Time Monitoring and Incident Prediction. In Journal of Artificial Intelligence and Big Data (Vol. 2, Issue 1, pp. 49–63). Science Publications (SCIPUB). https://doi.org/10.31586/jaibd.2022.1155

[21] Syed, S. (2023). Advanced Manufacturing Analytics: Optimizing Engine Performance through Real-Time Data and Predictive Maintenance. Letters in High Energy Physics, 2023, 184-195.

[22] Patra, G. K., Kuraku, C., Konkimalla, S., Boddapati, V. N., & Sarisa, M. (2023). Voice classification in AI: Harnessing machine learning for enhanced speech recognition. Global Research and Development Journals, 8(12), 19–26. https://doi.org/10.70179/grdjev09i110003

[23] Danda, R. R. (2023). Neural Network-Based Models For Predicting Healthcare Needs In International Travel Coverage Plans.

[24] Subhash Polineni, T. N., Pandugula, C., & Azith Teja Ganti, V. K. (2022). AI-Driven Automation in Monitoring Post-Operative Complications Across Health Systems. Global Journal of Medical Case Reports, 2(1), 1225. Retrieved from https://www.scipublications.com/journal/index.php/gjmcr/article/view/1225

[25] Nampalli, R. C. R. (2022). Machine Learning Applications in Fleet Electrification: Optimizing Vehicle Maintenance and Energy Consumption. In Educational Administration: Theory and Practice. Green Publication. https://doi.org/10.53555/kuey.v28i4.8258

[26] Syed, S. (2022). Towards Autonomous Analytics: The Evolution of Self-Service BI Platforms with Machine Learning Integration. In Journal of Artificial Intelligence and Big Data (Vol. 2, Issue 1, pp. 84–96). Science Publications (SCIPUB).https://doi.org/10.31586/jaibd.2022.1157

[27] Sunkara, J. R., Bauskar, S. R., Madhavaram, C. R., Galla, E. P., & Gollangi, H. K. (2023). Optimizing Cloud Computing Performance with Advanced DBMS Techniques: A Comparative Study. In Journal for ReAttach Therapy and Developmental Diversities. Green Publication. https://doi.org/10.53555/jrtdd.v6i10s(2).3206

[28] Mandala, G., Danda, R. R., Nishanth, A., Yasmeen, Z., & Maguluri, K. K. AI AND ML IN HEALTHCARE: REDEFINING DIAGNOSTICS, TREATMENT, AND PERSONALIZED MEDICINE.

[29] Kothapalli Sondinti, L. R., & Yasmeen, Z. (2022). Analyzing Behavioral Trends in Credit Card Fraud Patterns: Leveraging Federated Learning and Privacy-Preserving Artificial Intelligence Frameworks. Universal Journal of Business and Management, 2(1), 1224. Retrieved from https://www.scipublications.com/journal/index.php/ujbm/article/view/1224

[30] Rama Chandra Rao Nampalli. (2022). Deep Learning-Based Predictive Models For Rail Signaling And Control Systems: Improving Operational Efficiency And Safety. Migration Letters, 19(6), 1065–1077. Retrieved from https://migrationletters.com/index.php/ml/article/view/11335
[31] Syed, S. (2022). Integrating Predictive Analytics Into Manufacturing Finance: A Case Study On Cost Control And Zero-Carbon Goals In Automotive Production. Migration Letters, 19(6), 1078-1090.
[32] Rajaram, S. K., Konkimalla, S., Sarisa, M., Gollangi, H. K., Madhavaram, C. R., Reddy, M. S., (2023). AI/ML-Powered Phishing Detection: Building an Impenetrable Email Security System. ISAR Journal of Science and Technology, 1(2), 10-19.
[33] Danda, R. R., Maguluri, K. K., Yasmeen, Z., Mandala, G., & Dileep, V. (2023). Intelligent Healthcare Systems: Harnessing Ai and Ml To Revolutionize Patient Care And Clinical Decision-Making.
[34] Kothapalli Sondinti, L. R., & Syed, S. (2021). The Impact of Instant Credit Card Issuance and Personalized Financial Solutions on Enhancing Customer Experience in the Digital Banking Era. Universal Journal of Finance and Economics, 1(1), 1223. Retrieved from https://www.scipublications.com/journal/index.php/ujfe/article/view/1223
[35] Nampalli, R. C. R. (2021). Leveraging AI in Urban Traffic Management: Addressing Congestion and Traffic Flow with Intelligent Systems. In Journal of Artificial Intelligence and Big Data (Vol. 1, Issue 1, pp. 86–99). Science Publications (SCIPUB). https://doi.org/10.31586/jaibd.2021.1151
[36] Syed, S. (2021). Financial Implications of Predictive Analytics in Vehicle Manufacturing: Insights for Budget Optimization and Resource Allocation. Journal of Artificial Intelligence and Big Data, 1(1), 111–125. Retrieved from https://www.scipublications.com/journal/index.php/jaibd/article/view/1154
[37] Patra, G. K., Rajaram, S. K., Boddapati, V. N., Kuraku, C., & Gollangi, H. K. (2022). Advancing Digital Payment Systems: Combining AI, Big Data, and Biometric Authentication for Enhanced Security. International Journal of Engineering and Computer Science, 11(08), 25618–25631. https://doi.org/10.18535/ijecs/v11i08.4698
[38] Danda, R. R. Decision-Making in Medicare Prescription Drug Plans: A Generative AI Approach to Consumer Behavior Analysis.
[39] Vankayalapati, R. K., Edward, A., & Yasmeen, Z. (2022). Composable Infrastructure: Towards Dynamic Resource Allocation in Multi-Cloud Environments. Universal Journal of Computer Sciences and Communications, 1(1), 1222. Retrieved from https://www.scipublications.com/journal/index.php/ujcsc/article/view/1222
[40] Syed, S., & Nampalli, R. C. R. (2021). Empowering Users: The Role Of AI In Enhancing Self-Service BI For Data-Driven Decision Making. In Educational Administration: Theory and Practice. Green Publication. https://doi.org/10.53555/kuey.v27i4.8105
[41] Sarisa, M., Boddapati, V. N., Kumar Patra, G., Kuraku, C., & Konkimalla, S. (2022). Deep Learning Approaches To Image Classification: Exploring The Future Of Visual Data Analysis. In Educational Administration: Theory and Practice. Green Publication. https://doi.org/10.53555/kuey.v28i4.7863
[42] Danda, R. R. (2022). Application of Neural Networks in Optimizing Health Outcomes in Medicare Advantage and Supplement Plans. Journal of Artificial Intelligence and Big Data, 2(1), 97–111. Retrieved from https://www.scipublications.com/journal/index.php/jaibd/article/view/1178
[43] Syed, S., & Nampalli, R. C. R. (2020). Data Lineage Strategies – A Modernized View. In Educational Administration: Theory and Practice. Green Publication. https://doi.org/10.53555/kuey.v26i4.8104
[44] Sondinti, L. R. K., & Yasmeen, Z. (2022). Analyzing Behavioral Trends in Credit Card Fraud Patterns: Leveraging Federated Learning and Privacy-Preserving Artificial Intelligence Frameworks.
[45] Syed, S. (2019). Roadmap for Enterprise Information Management: Strategies and Approaches in 2019. International Journal of Engineering and Computer Science, 8(12), 24907–24917. https://doi.org/10.18535/ijecs/v8i12.4415
[46] Bauskar, S. R., Madhavaram, C. R., Galla, E. P., Sunkara, J. R., & Gollangi, H. K. (2022). PREDICTING DISEASE OUTBREAKS USING AI AND BIG DATA: A NEW FRONTIER IN HEALTHCARE ANALYTICS. In European Chemical Bulletin. Green Publication. https://doi.org/10.53555/ecb.v11:i12.17745
[47] Danda, R. R. (2022). Deep Learning Approaches For Cost-Benefit Analysis Of Vision And Dental Coverage In Comprehensive Health Plans. Migration Letters, 19(6), 1103-1118.
[48] Maguluri, K. K., Yasmeen, Z., & Nampalli, R. C. R. (2022). Big Data Solutions For Mapping Genetic Markers Associated With Lifestyle Diseases. Migration Letters, 19(6), 1188-1204.
[49] Eswar Prasad Galla.et.al. (2021). Big Data And AI Innovations In Biometric Authentication For Secure Digital Transactions Educational Administration: Theory and Practice, 27(4), 1228 –1236Doi: 10.53555/kuey.v27i4.7592
[50] Ramanakar Reddy Danda. (2022). Telehealth In Medicare Plans: Leveraging AI For Improved Accessibility And Senior Care Quality. Migration Letters, 19(6), 1133–1143. Retrieved from https://migrationletters.com/index.php/ml/article/view/11446
[51] Vankayalapati, R. K., & Syed, S. (2020). Green Cloud Computing: Strategies for Building Sustainable Data Center Ecosystems. Online Journal of Engineering Sciences, 1(1), 1229. Retrieved from https://www.scipublications.com/journal/index.php/ojes/article/view/1229

[52] Venkata Nagesh Boddapati, Eswar Prasad Galla, Janardhana Rao Sunkara, Sanjay Ramdas Bauskar, Gagan Kumar Patra, Chandrababu Kuraku, Chandrakanth Rao Madhavaram, 2021. "Harnessing the Power of Big Data: The Evolution of AI and Machine Learning in Modern Times", ESP Journal of Engineering & Technology Advancements, 1(2): 134-146.
[53] Danda, R. R. (2020). Predictive Modeling with AI and ML for Small Business Health Plans: Improving Employee Health Outcomes and Reducing Costs. In International Journal of Engineering and Computer Science (Vol. 9, Issue 12, pp. 25275–25288). Valley International. https://doi.org/10.18535/ijecs/v9i12.4572
[54] Vankayalapati, R. K., & Rao Nampalli, R. C. (2019). Explainable Analytics in Multi-Cloud Environments: A Framework for Transparent Decision-Making. Journal of Artificial Intelligence and Big Data, 1(1), 1228. Retrieved from https://www.scipublications.com/journal/index.php/jaibd/article/view/1228
[55] Mohit Surender Reddy, Manikanth Sarisa, Siddharth Konkimalla, Sanjay Ramdas Bauskar, Hemanth Kumar Gollangi, Eswar Prasad Galla, Shravan Kumar Rajaram, 2021. "Predicting tomorrow’s Ailments: How AI/ML Is Transforming Disease Forecasting", ESP Journal of Engineering & Technology Advancements, 1(2): 188-200.
[56] Ganti, V. K. A. T., & Pandugula, C. Tulasi Naga Subhash Polineni, Goli Mallesham (2023) Exploring the Intersection of Bioethics and AI-Driven Clinical Decision-Making: Navigating the Ethical Challenges of Deep Learning Applications in Personalized Medicine and Experimental Treatments. Journal of Material Sciences & Manufacturing Research. SRC/JMSMR-230. DOI: doi. org/10.47363/JMSMR/2023 (4), 192, 1-10.
[57] Chandrakanth R. M., Eswar P. G., Mohit S. R., Manikanth S., Venkata N. B., & Siddharth K. (2021). Predicting Diabetes Mellitus in Healthcare: A Comparative Analysis of Machine Learning Algorithms on Big Dataset. In Global Journal of Research in Engineering & Computer Sciences (Vol. 1, Number 1, pp. 1–11). https://doi.org/10.5281/zenodo.14010835
[58] Sondinti, L. R. K., & Syed, S. (2022). The Impact of Instant Credit Card Issuance and Personalized Financial Solutions on Enhancing Customer Experience in the Digital Banking Era. Finance and Economics, 1(1), 1223.
[59] Vaka, D. K. (2023). Achieving Digital Excellence In Supply Chain Through Advanced Technologies. Educational Administration: Theory and Practice, 29(4), 680-688.
[60] Sarisa, M., Boddapati, V. N., Patra, G. K., Kuraku, C., Konkimalla, S., & Rajaram, S. K. (2020). An Effective Predicting E-Commerce Sales & Management System Based on Machine Learning Methods. Journal of Artificial Intelligence and Big Data, 1(1), 75–85. Retrieved from https://www.scipublications.com/journal/index.php/jaibd/article/view/1110
[61] Vaka, D. K. Empowering Food and Beverage Businesses with S/4HANA: Addressing Challenges Effectively. J Artif Intell Mach Learn & Data Sci 2023, 1(2), 376-381.
[62] Gollangi, H. K., Bauskar, S. R., Madhavaram, C. R., Galla, E. P., Sunkara, J. R., & Reddy, M. S. (2020). Exploring AI Algorithms for Cancer Classification and Prediction Using Electronic Health Records. Journal of Artificial Intelligence and Big Data, 1(1), 65–74. Retrieved from https://www.scipublications.com/journal/index.php/jaibd/article/view/1109
[63] Vaka, D. K. “Artificial intelligence enabled Demand Sensing: Enhancing Supply Chain Responsiveness.
[64] Manikanth Sarisa, Venkata Nagesh Boddapati, Gagan Kumar Patra, Chandrababu Kuraku, Siddharth Konkimalla, Shravan Kumar Rajaram.Navigating the Complexities of Cyber Threats, Sentiment, and Health with AI/ML. (2020). JOURNAL OF RECENT TRENDS IN COMPUTER SCIENCE AND ENGINEERING (JRTCSE), 8(2), 22-40. https://doi.org/10.70589/JRTCSE.2020.2.3
[65] Vaka, D. K. (2020). Navigating Uncertainty: The Power of ‘Just in Time SAP for Supply Chain Dynamics. Journal of Technological Innovations, 1(2).
[66] Gollangi, H. K., Bauskar, S. R., Madhavaram, C. R., Galla, E. P., Sunkara, J. R., & Reddy, M. S. (2020).Unveiling the Hidden Patterns: AI-Driven Innovations in Image Processing and Acoustic Signal Detection. (2020). JOURNAL OF RECENT TRENDS IN COMPUTER SCIENCE AND ENGINEERING (JRTCSE), 8(1), 25-45. https://doi.org/10.70589/JRTCSE.2020.1.3.
[67] Dilip Kumar Vaka. (2019). Cloud-Driven Excellence: A Comprehensive Evaluation of SAP S/4HANA ERP. Journal of Scientific and Engineering Research. https://doi.org/10.5281/ZENODO.11219959
[68] Hemanth Kumar Gollangi, Sanjay Ramdas Bauskar, Chandrakanth Rao Madhavaram, Eswar Prasad Galla, Janardhana Rao Sunkara and Mohit Surender Reddy.(2020). “Echoes in Pixels: The intersection of Image Processing and Sound detection through the lens of AI and Ml”, International Journal of Development Research. 10,(08),39735-39743. https://doi.org/10.37118/ijdr.28839.28.2020.
[69] Manikanth Sarisa, Venkata Nagesh Boddapati, Gagan Kumar Patra, Chandrababu Kuraku, Siddharth Konkimalla and Shravan Kumar Rajaram. “The power of sentiment: big data analytics meets machine learning for emotional insights”, International Journal of Development Research, 10, (10), 41565-41573.